In-Hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: A report from the EVENT registry

Paul H. Tolerico, David J. Cohen, Neal S. Kleiman, Peter B. Berger, Emmanouil S. Brilakis, Robert N. Piana, Salim Shammo, Michelle J. Keyes, Kevin F. Kennedy, Joseph M. Massaro, Jorge F. Saucedo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives To compare outcomes of patients receiving drug-eluting stents (DES) versus bare metal stents (BMS) during percutaneous coronary intervention (PCI) of saphenous vein bypass grafts (SVG). Background Long-term benefits of DES versus BMS are well established for native vessel PCI. Benefit in patients undergoing SVG intervention is less certain. We used data from a multicenter registry (evaluation of drug eluting stents and ischemic events, EVENT) to compare outcomes among patients treated with DES versus BMS 1-year following SVG interventions. Methods Between July 2004 and December 2007, 684 patients in EVENT underwent SVG PCI (515 DES only, 169 BMS only). The primary endpoint was a composite of death, myocardial infarction (MI), and target lesion revascularization between hospital discharge and 1-year follow-up. Propensity score stratification was used to adjust for differences between groups. Results Baseline demographic and clinical characteristics of patients treated with DES and BMS were similar. The DES group had fewer men and a higher prevalence of prior PCI. Patients receiving DES had less angiographic thrombus, less frequent use of embolic protection devices, greater total stent length, and smaller maximum stent diameters. Unadjusted outcomes between discharge and 1-year follow-up did not differ between the groups. After risk adjustment, the primary outcome was less frequent among patients treated with DES (adjusted HR = 0.48, 95% CI = 0.27-0.84, P < 0.01) with similar relative benefits across the individual endpoints. Conclusions Among patients undergoing SVG PCI in a "real world" registry analyzed using propensity score stratification, treatment with DES compared with BMS was associated with reduced MACE at 1 year following PCI.

Original languageEnglish (US)
Pages (from-to)1127-1136
Number of pages10
JournalCatheterization and Cardiovascular Interventions
Volume80
Issue number7
DOIs
StatePublished - Dec 1 2012

Fingerprint

Drug-Eluting Stents
Saphenous Vein
Stents
Registries
Metals
Transplants
Percutaneous Coronary Intervention
Pharmaceutical Preparations
Propensity Score
Embolic Protection Devices
Risk Adjustment
Thrombosis
Myocardial Infarction
Demography

Keywords

  • coronary artery disease
  • coronary bypass grafts
  • percutaneous coronary intervention
  • stent

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

In-Hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention : A report from the EVENT registry. / Tolerico, Paul H.; Cohen, David J.; Kleiman, Neal S.; Berger, Peter B.; Brilakis, Emmanouil S.; Piana, Robert N.; Shammo, Salim; Keyes, Michelle J.; Kennedy, Kevin F.; Massaro, Joseph M.; Saucedo, Jorge F.

In: Catheterization and Cardiovascular Interventions, Vol. 80, No. 7, 01.12.2012, p. 1127-1136.

Research output: Contribution to journalArticle

Tolerico, PH, Cohen, DJ, Kleiman, NS, Berger, PB, Brilakis, ES, Piana, RN, Shammo, S, Keyes, MJ, Kennedy, KF, Massaro, JM & Saucedo, JF 2012, 'In-Hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: A report from the EVENT registry', Catheterization and Cardiovascular Interventions, vol. 80, no. 7, pp. 1127-1136. https://doi.org/10.1002/ccd.24352
Tolerico, Paul H. ; Cohen, David J. ; Kleiman, Neal S. ; Berger, Peter B. ; Brilakis, Emmanouil S. ; Piana, Robert N. ; Shammo, Salim ; Keyes, Michelle J. ; Kennedy, Kevin F. ; Massaro, Joseph M. ; Saucedo, Jorge F. / In-Hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention : A report from the EVENT registry. In: Catheterization and Cardiovascular Interventions. 2012 ; Vol. 80, No. 7. pp. 1127-1136.
@article{e85a649851f24425a14e3842544d856e,
title = "In-Hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: A report from the EVENT registry",
abstract = "Objectives To compare outcomes of patients receiving drug-eluting stents (DES) versus bare metal stents (BMS) during percutaneous coronary intervention (PCI) of saphenous vein bypass grafts (SVG). Background Long-term benefits of DES versus BMS are well established for native vessel PCI. Benefit in patients undergoing SVG intervention is less certain. We used data from a multicenter registry (evaluation of drug eluting stents and ischemic events, EVENT) to compare outcomes among patients treated with DES versus BMS 1-year following SVG interventions. Methods Between July 2004 and December 2007, 684 patients in EVENT underwent SVG PCI (515 DES only, 169 BMS only). The primary endpoint was a composite of death, myocardial infarction (MI), and target lesion revascularization between hospital discharge and 1-year follow-up. Propensity score stratification was used to adjust for differences between groups. Results Baseline demographic and clinical characteristics of patients treated with DES and BMS were similar. The DES group had fewer men and a higher prevalence of prior PCI. Patients receiving DES had less angiographic thrombus, less frequent use of embolic protection devices, greater total stent length, and smaller maximum stent diameters. Unadjusted outcomes between discharge and 1-year follow-up did not differ between the groups. After risk adjustment, the primary outcome was less frequent among patients treated with DES (adjusted HR = 0.48, 95{\%} CI = 0.27-0.84, P < 0.01) with similar relative benefits across the individual endpoints. Conclusions Among patients undergoing SVG PCI in a {"}real world{"} registry analyzed using propensity score stratification, treatment with DES compared with BMS was associated with reduced MACE at 1 year following PCI.",
keywords = "coronary artery disease, coronary bypass grafts, percutaneous coronary intervention, stent",
author = "Tolerico, {Paul H.} and Cohen, {David J.} and Kleiman, {Neal S.} and Berger, {Peter B.} and Brilakis, {Emmanouil S.} and Piana, {Robert N.} and Salim Shammo and Keyes, {Michelle J.} and Kennedy, {Kevin F.} and Massaro, {Joseph M.} and Saucedo, {Jorge F.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1002/ccd.24352",
language = "English (US)",
volume = "80",
pages = "1127--1136",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - In-Hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention

T2 - A report from the EVENT registry

AU - Tolerico, Paul H.

AU - Cohen, David J.

AU - Kleiman, Neal S.

AU - Berger, Peter B.

AU - Brilakis, Emmanouil S.

AU - Piana, Robert N.

AU - Shammo, Salim

AU - Keyes, Michelle J.

AU - Kennedy, Kevin F.

AU - Massaro, Joseph M.

AU - Saucedo, Jorge F.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Objectives To compare outcomes of patients receiving drug-eluting stents (DES) versus bare metal stents (BMS) during percutaneous coronary intervention (PCI) of saphenous vein bypass grafts (SVG). Background Long-term benefits of DES versus BMS are well established for native vessel PCI. Benefit in patients undergoing SVG intervention is less certain. We used data from a multicenter registry (evaluation of drug eluting stents and ischemic events, EVENT) to compare outcomes among patients treated with DES versus BMS 1-year following SVG interventions. Methods Between July 2004 and December 2007, 684 patients in EVENT underwent SVG PCI (515 DES only, 169 BMS only). The primary endpoint was a composite of death, myocardial infarction (MI), and target lesion revascularization between hospital discharge and 1-year follow-up. Propensity score stratification was used to adjust for differences between groups. Results Baseline demographic and clinical characteristics of patients treated with DES and BMS were similar. The DES group had fewer men and a higher prevalence of prior PCI. Patients receiving DES had less angiographic thrombus, less frequent use of embolic protection devices, greater total stent length, and smaller maximum stent diameters. Unadjusted outcomes between discharge and 1-year follow-up did not differ between the groups. After risk adjustment, the primary outcome was less frequent among patients treated with DES (adjusted HR = 0.48, 95% CI = 0.27-0.84, P < 0.01) with similar relative benefits across the individual endpoints. Conclusions Among patients undergoing SVG PCI in a "real world" registry analyzed using propensity score stratification, treatment with DES compared with BMS was associated with reduced MACE at 1 year following PCI.

AB - Objectives To compare outcomes of patients receiving drug-eluting stents (DES) versus bare metal stents (BMS) during percutaneous coronary intervention (PCI) of saphenous vein bypass grafts (SVG). Background Long-term benefits of DES versus BMS are well established for native vessel PCI. Benefit in patients undergoing SVG intervention is less certain. We used data from a multicenter registry (evaluation of drug eluting stents and ischemic events, EVENT) to compare outcomes among patients treated with DES versus BMS 1-year following SVG interventions. Methods Between July 2004 and December 2007, 684 patients in EVENT underwent SVG PCI (515 DES only, 169 BMS only). The primary endpoint was a composite of death, myocardial infarction (MI), and target lesion revascularization between hospital discharge and 1-year follow-up. Propensity score stratification was used to adjust for differences between groups. Results Baseline demographic and clinical characteristics of patients treated with DES and BMS were similar. The DES group had fewer men and a higher prevalence of prior PCI. Patients receiving DES had less angiographic thrombus, less frequent use of embolic protection devices, greater total stent length, and smaller maximum stent diameters. Unadjusted outcomes between discharge and 1-year follow-up did not differ between the groups. After risk adjustment, the primary outcome was less frequent among patients treated with DES (adjusted HR = 0.48, 95% CI = 0.27-0.84, P < 0.01) with similar relative benefits across the individual endpoints. Conclusions Among patients undergoing SVG PCI in a "real world" registry analyzed using propensity score stratification, treatment with DES compared with BMS was associated with reduced MACE at 1 year following PCI.

KW - coronary artery disease

KW - coronary bypass grafts

KW - percutaneous coronary intervention

KW - stent

UR - http://www.scopus.com/inward/record.url?scp=85027921635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027921635&partnerID=8YFLogxK

U2 - 10.1002/ccd.24352

DO - 10.1002/ccd.24352

M3 - Article

C2 - 22431166

AN - SCOPUS:85027921635

VL - 80

SP - 1127

EP - 1136

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 7

ER -